CSIMarket
 
Centogene N v   (CNTG)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $0.7000 $0.00 -0.540%
Day's High: $0.7171 Week Perf: -26.14 %
Day's Low: $ 0.63 30 Day Perf: -38.86 %
Volume (M): 52 52 Wk High: $ 2.52
Volume (M$): $ 36 52 Wk Avg: $1.04
Open: $0.63 52 Wk Low: $0.61



 Market Capitalization (Millions $) 19
 Shares Outstanding (Millions) 27
 Employees 500
 Revenues (TTM) (Millions $) 53
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) 20
 Capital Exp. (TTM) (Millions $) 0

Centogene N V
Centogene N V is a Netherlands-based company that operates in the genetic testing and diagnostics industry. The company specializes in the diagnostics of rare and genetic diseases as well as the provision of personalized medicine solutions. Centogene was founded in 2006 and has since then developed a unique approach to diagnosing rare diseases through its proprietary CentoMDe database.

The company's platform aims to provide a comprehensive understanding of the genetic basis of rare diseases, and they offer a wide range of diagnostic genetic testing services including targeted gene sequencing, whole-exome sequencing, whole-genome sequencing, and bioinformatics analysis. Their tests are performed using state-of-the-art technology and are designed to provide accurate and reliable results.

Centogene has developed a digitalized platform that connects the company's diagnostic services and proprietary database with the global medical community, providing an innovative ecosystem that enables physicians and researchers to collaborate easily and efficiently. As a result of this approach, Centogene has established partnerships with a wide range of stakeholders, including pharmaceutical and biotech companies, academic institutions, and patient organizations.

The company's mission is to improve the lives of patients by providing accurate diagnoses and personalized medicine solutions that can positively impact their treatment and disease management. To achieve this goal, Centogene N V invests heavily in research and development, collaborating with top academic institutions and pharmaceutical companies to innovate and improve its services.

Overall, Centogene N V is a leader in the genetic diagnostics industry, combining state-of-the-art technology with innovation and collaboration to improve patient care and disease management.


   Company Address: Am Strande 7 Rostock 18055
   Company Phone Number: 381 80113 500   Stock Exchange / Ticker: NASDAQ CNTG
   CNTG is expected to report next financial results on May 15, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Centogene Sets Course for Sustainable Growth Through Strategic Alternatives

Published Wed, Feb 28 2024 11:30 AM UTC

In a significant development, Centogene N.V., a leading provider of data-driven solutions in rare and neurodegenerative diseases, has recently announced its decision to explore various strategic alternatives aimed at delivering long-term value for its stakeholders. Based in Cambridge, Massachusetts, with operations in Rostock, Germany, and Berlin, the Company is well-positio...

Stock Market Announcement

Navigating the Delisting Notice: Analyzing the Potential Implications on Company Securities

Published Wed, Feb 28 2024 11:31 AM UTC



In a recent press release, a prominent company has announced the receipt of a delisting notice, sparking concerns among investors and market participants. The market is closely watching the development with bated breath, curious about the consequences and the company's next steps. With this notice, it is crucial to delve into the details and understand the potentia...

Contract

Leveraging Diversified Data: A Collaborative Approach towards Accelerating Rare Disease Drug Discovery

Published Thu, Jan 25 2024 11:30 AM UTC

In the world of rare diseases, where finding effective treatments is often a challenging and time-consuming endeavor, a recent collaboration between CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine comes as a ray of hope. The joint efforts of both organizations aim to leverage diversified data for accelerating drug discovery and clini...

Management Announcement

Fueling Medical Research: CENTOGENE Receives French Accreditation for Research Tax Credit

Published Wed, Jan 24 2024 11:31 AM UTC



CENTOGENE, a leading global provider of diagnostic and research solutions in rare diseases, has announced its successful accreditation for the French Research Tax Credit. This achievement allows CENTOGENE's partners to claim up to 30% tax relief, thereby providing significant financial advantages and promoting further collaboration in the field of medical research....

Clinical Study

Unveiling the Genetic Mystery: Collaborative Research to Validate Parkinson's Disease Risk Factors Using Multiomics

Published Tue, Jan 23 2024 11:31 AM UTC

Parkinson's Disease (PD) is a chronic neurological disorder that affects millions of people worldwide, causing tremors, stiffness, and difficulties in motor function. Despite extensive research, the exact causes of PD still remain elusive. However, recent advancements in the field of genetics have opened up new possibilities for understanding the underlying genetic risk fact...






 

Centogene N V's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com